pharmaceuticals
reports
third
quarter
financial
results
provides
corporate
update
nasdaq
xfor
whim
phase
data
published
blood
official
journal
american
society
hematology
granted
fast
track
designation
fda
mavorixafor
whim
syndrome
key
leadership
appointments
including
cso
board
director
conference
call
today
et
boston
globe
newswire
pharmaceuticals
nasdaq
xfor
leader
discovery
development
novel
therapies
targeting
diseases
resulting
dysfunction
pathway
today
reported
financial
results
third
quarter
ended
september
company
also
provided
update
lead
investigational
candidate
mavorixafor
novel
small
molecule
phase
clinical
trial
patients
whim
warts
hypogammaglobulinemia
infections
myelokathexis
syndrome
two
phase
trials
patients
waldenström
macroglobulinemia
severe
congenital
neutropenia
scn
respectively
third
quarter
highlighted
publication
positive
phase
safety
efficacy
data
mavorixafor
whim
syndrome
prestigious
journal
blood
believe
continues
demonstrate
significant
potential
lead
candidate
treat
patient
population
said
paula
ragan
president
chief
executive
officer
pharmaceuticals
early
october
announced
food
drug
administration
fda
granted
mavorixafor
fast
track
designation
treatment
whim
facilitating
expedited
review
mavorixafor
proceed
clinical
development
achievements
enhance
confidence
mavorixafor
potential
deliver
first
therapy
undertreated
patient
population
also
thrilled
enhance
leadership
team
expertise
additions
art
taveras
chief
scientific
officer
new
board
member
alison
ragan
continued
operating
environment
remains
challenging
due
ongoing
pandemic
continue
advance
mavorixafor
development
programs
enroll
patients
clinical
trials
anticipate
initial
data
phase
waldenström
macroglobulinemia
trial
first
half
along
initial
data
phase
trial
patients
scn
results
phase
trial
mavorixafor
whim
syndrome
continue
achieve
important
clinical
progress
ragan
concluded
supported
strong
balance
sheet
expect
drive
current
strategic
development
plans
early
recent
highlights
published
comprehensive
data
phase
open
label
extension
study
mavorixafor
whim
syndrome
blood
official
journal
american
society
hematology
expanding
previously
presented
data
new
results
included
data
regarding
effect
neutrophils
lymphocytes
effect
increasing
doses
mavorixafor
total
white
blood
cell
counts
monocytes
addition
manuscript
provided
pharmacokinetic
data
presented
detailed
analysis
clinical
improvements
infection
rates
warts
demonstrated
extended
mavorixafor
treatment
expanding
previously
presented
data
new
results
included
data
regarding
effect
neutrophils
lymphocytes
effect
increasing
doses
mavorixafor
total
white
blood
cell
counts
monocytes
addition
manuscript
provided
pharmacokinetic
data
presented
detailed
analysis
clinical
improvements
infection
rates
warts
demonstrated
extended
mavorixafor
treatment
granted
fast
track
designation
fda
mavorixafor
whim
syndrome
fast
track
program
eligible
frequent
meetings
fda
discuss
mavorixafor
development
plan
protocols
clinical
data
would
support
potential
approval
whim
mavorixafor
previously
granted
breakthrough
therapy
designation
fda
well
orphan
drug
status
fda
european
commission
treatment
whim
syndrome
fast
track
program
eligible
frequent
meetings
fda
discuss
mavorixafor
development
plan
protocols
clinical
data
would
support
potential
approval
whim
mavorixafor
previously
granted
breakthrough
therapy
designation
fda
well
orphan
drug
status
fda
european
commission
treatment
whim
syndrome
appointed
art
taveras
chief
scientific
officer
taveras
seasoned
chief
scientific
officer
experience
discovery
novel
antagonists
treatment
cancer
previously
taveras
vp
small
molecule
drug
discovery
biogen
president
cso
shangpharma
chempartners
cso
comet
therapeutics
expertise
chemistries
taveras
well
suited
lead
r
initiatives
continued
evolution
global
rare
disease
company
taveras
seasoned
chief
scientific
officer
experience
discovery
novel
antagonists
treatment
cancer
previously
taveras
vp
small
molecule
drug
discovery
biogen
president
cso
shangpharma
chempartners
cso
comet
therapeutics
expertise
chemistries
taveras
well
suited
lead
r
initiatives
continued
evolution
global
rare
disease
company
expanded
board
directors
appointment
biopharmaceutical
industry
veteran
alison
lawton
lawton
strengthens
board
drug
development
manufacturing
commercialization
experience
brings
unique
understanding
core
scientific
corporate
goals
previously
served
consulting
chief
operating
officer
company
member
corporate
advisory
board
lawton
year
tenure
genzyme
corporation
sanofi
genzyme
including
senior
vice
president
general
manager
sanofi
biosurgery
million
business
led
global
functional
organizations
including
regulatory
affairs
quality
systems
public
policy
health
outcomes
strategic
pricing
product
safety
risk
management
lawton
recently
served
ceo
kaleido
biosciences
currently
serves
independent
director
board
proqr
therapeutics
nv
third
quarter
financial
results
cash
cash
equivalents
restricted
cash
million
cash
cash
equivalents
restricted
cash
september
continues
expect
cash
cash
equivalents
fund
company
operations
early
note
guidance
include
million
potential
contingent
proceeds
hercules
debt
facility
cash
exercise
proceeds
investors
holding
outstanding
warrants
million
cash
cash
equivalents
restricted
cash
september
continues
expect
cash
cash
equivalents
fund
company
operations
early
note
guidance
include
million
potential
contingent
proceeds
hercules
debt
facility
cash
exercise
proceeds
investors
holding
outstanding
warrants
research
development
expenses
million
third
quarter
ended
september
compared
million
comparable
period
r
expenses
include
million
certain
expenses
quarter
ended
september
million
third
quarter
ended
september
compared
million
comparable
period
r
expenses
include
million
certain
expenses
quarter
ended
september
general
administrative
expenses
million
third
quarter
ended
september
compared
million
comparable
period
g
expenses
include
million
certain
expenses
quarter
ended
september
million
third
quarter
ended
september
compared
million
comparable
period
g
expenses
include
million
certain
expenses
quarter
ended
september
net
loss
reported
net
loss
million
third
quarter
ended
september
compared
net
loss
million
comparable
period
net
loss
includes
million
certain
expenses
quarter
ended
september
net
loss
third
quarter
included
million
loss
sale
assets
conference
call
webcast
company
host
conference
call
webcast
today
et
discuss
financial
results
business
highlights
conference
call
accessed
dialing
united
states
internationally
followed
conference
id
live
webcast
accessed
investor
relations
section
pharmaceuticals
website
following
completion
call
webcast
replay
conference
call
available
website
pharmaceuticals
pharmaceuticals
clinical
biopharmaceutical
company
leader
discovery
development
novel
therapies
treatment
diseases
resulting
dysfunction
pathway
focus
rare
diseases
limited
treatment
options
company
lead
candidate
mavorixafor
small
molecule
antagonist
chemokine
receptor
developed
oral
therapy
believes
inhibition
receptor
creates
potential
mavorixafor
provide
therapeutic
benefit
across
wide
variety
diseases
including
primary
immunodeficiencies
certain
types
cancer
efficacy
safety
mavorixafor
dosed
daily
currently
evaluated
global
phase
clinical
trial
patients
whim
syndrome
two
phase
clinical
trials
combination
ibrutinib
patients
waldenström
macroglobulinemia
monotherapy
patients
severe
congenital
neutropenia
continuing
leverage
insights
biology
corporate
headquarters
boston
massachusetts
research
facility
vienna
austria
discovering
developing
additional
product
candidates
information
please
visit
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
statements
may
identified
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
terms
expressions
concern
expectations
strategy
plans
intentions
statements
include
without
limitation
statements
regarding
clinical
development
mavorixafor
whim
waldenström
macroglobulinemia
scn
product
candidates
programs
fast
track
designation
statements
press
release
based
management
current
expectations
beliefs
actual
events
results
may
differ
materially
expressed
implied
statements
contained
herein
including
without
limitation
risks
uncertainties
described
section
entitled
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
filings
makes
sec
time
time
undertakes
obligation
update
information
contained
press
release
reflect
new
events
circumstances
except
required
law
pharmaceuticals
condensed
consolidated
statements
operations
thousands
except
per
share
amounts
unaudited
three
months
ended
nine
months
ended
september
september
license
revenue
operating
expenses
research
development
general
administrative
loss
transfer
assets
total
operating
expenses
loss
operations
expense
net
loss
provision
income
taxes
provision
income
taxes
net
loss
adjustments
related
convertible
preferred
stock
net
loss
attributable
common
stockholders
net
loss
per
share
attributable
common
basic
diluted
weighted
average
common
shares
diluted
pharmaceuticals
condensed
consolidated
statements
cash
flows
thousands
unaudited
nine
months
ended
september
net
loss
adjustments
reconcile
net
loss
net
cash
used
operating
activities
changes
operating
assets
liabilities
net
cash
used
operating
activities
net
cash
used
provided
investing
activities
net
cash
provided
financing
activities
impact
foreign
exchange
cash
cash
equivalents
restricted
cash
net
decrease
increase
cash
cash
equivalents
restricted
cash
cash
cash
equivalents
restricted
cash
beginning
period
cash
cash
equivalents
restricted
cash
end
period
pharmaceuticals
condensed
consolidated
balance
sheets
thousands
unaudited
september
december
current
assets
cash
cash
equivalents
research
development
incentive
receivable
prepaid
expenses
current
assets
total
current
assets
property
equipment
net
goodwill
assets
assets
total
assets
current
liabilities
accounts
payable
accrued
expenses
current
portion
lease
liability
total
current
liabilities
debt
including
accretion
net
discount
lease
liabilities
liabilities
total
liabilities
total
stockholders
equity
total
liabilities
stockholders
equity
investors
media
daniel
ferry
managing
director
lifesci
advisors
daniel
